PLC Systems Inc. (OTC:PLCSF) is touting more results from a clinical study of its RenalGuard contrast-induced nephropathy treatment.
CIN is a form of acute renal failure caused by exposure to contrast media agents during image-guided cardiology and radiology procedures. The Franklin, Mass.-based company said data on 105 patients with chronic kidney disease indicate that only 4 percent of the patients treated with RenalGuard acquired the malady. The results, presented at last month’s American Heart Assn. Scientific Sessions 2009, are consistent with expectations set by the company after preliminary results were released in August.